罗沙司他与阿法依泊汀治疗透析慢性肾脏病患者贫血:随机3期ROCKIES研究结果
ROCKIES是一项开放标签3期随机研究,纳入2133例透析依赖慢性肾脏病伴贫血患者,按1:1随机接受口服罗沙司他每周三次或按当地诊所常规胃肠外阿法依泊汀。第28至52周平均血红蛋白较基线变化罗沙司他组为0.77 g/dl、阿法依泊汀组为0.68 g/dl,达到非劣效;不良事件谱与阿法依泊汀相当。
要点
- 罗沙司他组血红蛋白较基线变化0.77 g/dl,阿法依泊汀组0.68 g/dl,达到非劣效
- 主要终点最小二乘均值差0.09 g/dl(95%CI 0.01至0.18),P<0.001
- 罗沙司他与阿法依泊汀不良事件谱相当
核心结论
- 罗沙司他有效提高透析依赖慢性肾脏病患者的血红蛋白,不良事件谱与阿法依泊汀相当。
研究设计与样本
- 开放标签3期随机研究,透析依赖慢性肾脏病伴贫血患者按1:1随机接受口服罗沙司他每周三次或按当地诊所常规胃肠外阿法依泊汀,共2133例(罗沙司他组1068例,阿法依泊汀组1065例)。
- 罗沙司他初始剂量对已在用促红细胞生成素刺激剂者取决于筛查时该药剂量,对未用者为按体重计算。
- 主要疗效终点为第28至52周平均血红蛋白较基线变化,不考虑补救治疗使用,检验非劣效(界值-0.75 g/dl)。
- 患者平均年龄54.0岁,血液透析占89.1%,腹膜透析占10.8%。
主要发现
- 血红蛋白较基线变化均值(95%CI)罗沙司他组为0.77(0.69至0.85)g/dl,阿法依泊汀组为0.68(0.60至0.76)g/dl。
- 最小二乘均值差(95%CI)为0.09(0.01至0.18)g/dl,P<0.001,达到非劣效。
- 发生至少1例不良事件的比例罗沙司他组为85.0%、阿法依泊汀组为84.5%,发生至少1例严重不良事件的比例分别为57.6%和57.5%。
关键数值与推荐
- 非劣效界值为-0.75 g/dl。
- 主要终点为第28至52周平均血红蛋白较基线变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concerns regarding cardiovascular safety with current treatments for anemia in patients with dialysis-dependent (DD)-CKD have encouraged the development of alternatives. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing endogenous erythropoietin and iron availability. METHODS: In this open-label phase 3 study, patients with DD-CKD and anemia were randomized 1:1 to oral roxadustat three times weekly or parenteral epoetin alfa per local clinic practice. Initial roxadustat dose depended on erythropoiesis-stimulating agent dose at screening for patients already on them and was weight-based for those not on them. The primary efficacy end point was mean hemoglobin change from baseline averaged over weeks 28‒52 for roxadustat versus epoetin alfa, regardless of rescue therapy use, tested for noninferiority (margin, -0.75 g/dl). Adverse events (AEs) were assessed. RESULTS: Among 2133 patients randomized (n=1068 roxadustat, n=1065 epoetin alfa), mean age was 54.0 years, and 89.1% and 10.8% were on hemodialysis and peritoneal dialysis, respectively. Mean (95% confidence interval) hemoglobin change from baseline was 0.77 (0.69 to 0.85) g/dl with roxadustat and 0.68 (0.60 to 0.76) g/dl with epoetin alfa, demonstrating noninferiority (least squares mean difference [95% CI], 0.09 [0.01 to 0.18]; P<0.001). The proportion of patients experiencing ≥1 AE and ≥1 serious AE was 85.0% and 57.6% with roxadustat and 84.5% and 57.5% with epoetin alfa, respectively. CONCLUSIONS: Roxadustat effectively increased hemoglobin in patients with DD-CKD, with an AE profile comparable to epoetin alfa. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. CLINICALTRIALS: gov Identifier: NCT02174731.
引用
- Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. J Am Soc Nephrol. 2022. PMID: 35361724. doi:10.1681/ASN.2020111638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。